Science:  TMi’s science includes a research model of dry AMD that faithfully mimics disease, developing both late disease and the high-risk features of patients at risk. With unprecedented similarities to clinical disease, new treatments can be tested with greater predictive value when moving from bench to bedside.

Medicine:  Patients with early dry AMD accumulate little deposits known as drusen.  Some patients at particularly high risk of vision loss may also develop what are known as pseudodrusen  Late in disease, drusen and pseudodrusen give way to patches of tissue loss known as Geographic Atrophy (GA).

Pharma:  The path from Science to Medicine can be slow.  TMi solves this critical hurdle by re-formulating an investigational new drug already demonstrated to be safe in Phase II clinical trial for non-ophthalmic indications. Our plan is to develop this drug for the eye, specifically for the treatment of AMD.   Further, TMi uniquely aligns its pre-clinical markers of clinical trial endpoints approved by the US FDA.  Together, these steps shave years off the time taken to find a cure.